Objectives: Heart transplantation is the best therapeutic option for patients suffering from end-stage heart failure, but donor organ availability still represents a major problem. This had led to a shift toward extended donor criteria. The aim of the present study is to analyze the short-and long-term results of heart transplantation in patients with donor age !60 years. Methods: Since November 1985, 890 patients have been transplanted at our center. We consider, for the present study, only primary adult heart transplantations performed after 1990, totaling 761 patients, mean age at transplantation 49.8 years, and 616 patients being male (81%). We compare the short-and long-term results of patients transplanted with donors younger than 60 years or !60 years. Results: Since 1990, at our center, 711 patients have been heart transplanted with a donor younger than 60 years, while 50 patients received a heart from a donor older than 60 years. No differences have been reported in the etiology of cardiomyopathy, previous surgery, or mean ischemic time. Patients transplanted with donors !60 years of age were significantly older compared to the younger donors' group. Donor cause of death was a cerebrovascular accident in 82% of donors !60 years versus 41% in younger donors. Patients' heart transplanted with donors !60 years had a higher incidence of acute graft failure with a hospital mortality of 32% (16 patients) significantly higher compared with 10.2% for the other group. No differences were noticed in the incidence of renal failure, acute rejection treated, coronary allograft vasculopathy, and neoplasm during long-term follow-up. Conclusions: It was possible to expand the cardiac donor pool by accepting allografts from donors !60 years of age in selected cases by performing a coronary angiogram. A meticulous donor evaluation and a careful risk assessment between the risk of death on the waiting list and probable increased hospital mortality are needed. #
Introduction
Heart transplantation (HTx) is the treatment of choice for many patients with end-stage heart failure (HF), who remain symptomatic despite optimal medical therapy; however, donor organ availability still represents a major limiting factor. Of an estimated 25 000 patients, who might potentially benefit from transplantation, fewer than 2500 undergo the procedure each year in the United States [1] . To overcome this limitation, different options have been studied, including improved professional and public educational programs and legislative changes. The most effective immediate answer to improve donor availability was the use of the so-called 'marginal donors'; organs that not long ago would have been considered unsuitable for transplantation are now being used. Marginal donors' criteria generally included older donors, diabetes mellitus, hepatitis Cpositive, ejection fraction <45%, and donor/recipient weight ratio <0.7 [2] . Evidence of this change in graft usage is an augmentation in mean donor age for HTx that increased from a low of 23 years in 1983 to 31 years by 1999, and has reached 33.6 years in the most recent cohort [3] . Donors !50 years, who were rarely reported prior to 1986, now account for 12%, and donors !60 years account for approximately 1.4% of all donors [1] . Despite the extended use of this particular donor population, some controversy exists about the short-and long-term outcome of this practice. Multicenter registries have consistently illustrated a linear relationship between increasing donor age and increasing mortality [3, 4] . Even if the use of donor hearts older than 50 years has been supported by multiple large single-center reports [5, 6] demonstrating equivalent survival compared with the use of younger donor organs, a much smaller experience currently supports the use of donor hearts over 60 years, generally in an alternative list strategy [2] . The aim of our study was to evaluate our single-institution experience in HTx with donors !60 years, to establish if extension of donor selection criteria have impacted significantly on early outcome after cardiac transplantation and to attempt to identify any predictors of adverse outcome.
Patients and methods

Study population
Between November 1985 and June 2010, 890 patients have been heart transplanted at our center. We consider for the present analysis only 761 patients, mean age at HTx 49.8 years, 616 being male (81%), and all primary adult (age >15 years) HTx performed after 1990, when the first donor heart !60 years old was accepted at our center. Donor, recipient, operative data, and follow-up were retrospectively collected on all consecutive heart transplants from our institutional HTx database. We compare the short-and long-term results of patients transplanted with a donor heart older than 60 years.
Recipient data included demographics and pre-transplant clinical characteristics: etiology of HF, presence of diabetes mellitus, vasculopathy, pulmonary arterial pressures, cardiac output, necessity of pre-transplant ventricular assist device (VAD) support, need of inotrope infusion, history of previous sternotomy, list status at transplantation, and renal function. Donor data included demographics, cause of death, coronary angiographic anatomy (if available), necessity of inotrope infusion, and ischemic time considered as the time between cross-clamp of the donor aorta to reperfusion of the heart after recipient aortic clamp removal. Outcome variables analyzed included graft failure, defined as severe dysfunction of the cardiac allograft without any anatomic or immunologic cause, severe right-ventricular failure, need of high-dose inotropic support or intra-aortic balloon pump (IABP), severe renal failure (creatinine >3 mg dl À1 ), hepatic failure (bilirubin >4 mg dl À1 ), infections, rejection treated, coronary allograft vasculopathy (CAV) defined as a new !50% lesion in any epicardial coronary artery detected by angiography, and survival. Hospital documentation and autopsy data were used to determine the recipient cause of death.
Donor procurement, surgical technique, and postoperative patient care
Donor assessment was based on a complete clinical and laboratory evaluation and transthoracic echocardiography. Angiography was generally requested in males with an age >45 years, females with an age >50 years, or in younger donors with cardiac risk factors. The biatrial anastomotic technique described by Lower and colleagues [7] was used until 1994; afterwards, the bicaval anastomosis technique has been routinely performed. The overall immunosuppressive protocol was substantially the same for all patients, consisting of triple therapy with steroids, azathioprine, and cyclosporine (CyA). Induction immunosuppression was obtained using rabbit antithymocyte globulins (RATGs) (ATG-Fresenius; Bad Homburg, Germany) given 2.5 mg kg À1 intra-operatively and 1-2 mg kg À1 day À1 for 4 days. Methylprednisolone was administered during surgery (500 mg) and then 250 mg intravenously every 12 h for three doses postoperatively; followed by prednisone 0.8 mg kg À1 day
À1
and progressively tapered to 0.2 mg kg À1 day À1 within the 11th postoperative day. Azathioprine was administered intravenously at time of surgery (3 mg kg À1 ) and maintained at 1.5 mg kg À1 day À1 postoperatively, according to peripheral leukocyte count. Cyclosporine was started soon after surgery (6-12 h after HTx) and gradually increased to obtain whole blood levels of 350-450 ng ml À1 . Clinical and echocardiographic follow-up were performed at our outpatients' ambulatory. Invasive evaluation protocol includes weekly endomyocardial biopsy in the first month, every 15 days till the third month, then at 4th, 5th, 6th, 9th, and 12th month. Hemodynamic evaluation and coronary arteriography were done 1 year after transplantation and were thereafter clinically driven. Follow-up was complete in all cases and was updated on 31 July 2010. Detailed enlisting criteria and donor and recipient monitoring have been previously described [8, 9] .
Statistical analysis
Results are expressed as mean AE standard deviation (SD) or as proportions (%). Differences between groups were evaluated by chi-square analysis or Fisher's exact test for binary and polychotomous variables and by Student's t-test for continuous variables.
Survival estimates were computed by the use of KaplanMeier methods and compared through log-rank tests. We estimated the median follow-up time with the reverse Kaplan-Meier method, that is, the Kaplan-Meier method with the event indicator reversed so that the outcome of interest becomes the fact of being censored. Follow-up was curtailed at 4124 days (11.3 years) to have a probability of remaining in follow-up of at least 50%. Relationships of event incidence to covariates were investigated with univariate Cox regression models. The proportional hazard assumption was checked for all screened covariates, and no relevant violations were found. The multivariable Cox regression model with a stepwise selection procedure was used to assess independent predictors of the follow-up event. An entry criterion of 0.10 and a stay criterion 0.05 were applied. Data were analyzed with Statistical Package for Social Sciences (SPSS) for Windows, release 16.0 (SPSS Inc., Chicago, IL, USA). All p values were two-sided and values <0.05 were considered statistically significant.
Results
At our center, mean donor age increased constantly over years, from a low of 25 years at the beginning of our experience to 37 years by the 1990s and reached 44.8 years in the most recent cohort (Fig. 1) . Donors !60 years, which event was never reported prior to 1990, in the past years account for more than 15% of all donors. Yearly use of donor hearts at least 60 years of age ranged, in our experience, between one and seven, and was highest in 2009.
Among our population of adult HTx, since 1990, 711 patients (93.4%) have been heart transplanted with a donor
younger than 60 years (group Y), while 50 patients received a heart from a donor 60 years of age or older (group O). Preheart transplant patients' characteristics are reported in Table 1 ; no differences in etiology of cardiomyopathy, hemodynamic status, end-organ function, status at HTx, number of previous cardiac operations, or VAD support were noticed between the two groups. The only observed difference was patients' age at HTx; group O HTx patients were older than recipients of younger donor hearts at 58.6 years versus 48.8 ( p < 0.0001). Table 2 details the clinical characteristics of donors. A significant statistical difference was evident, as expected, between donors of hearts at least 60 years with a mean age of 35.8 years compared with 62.5 years in donors of group O. Further, donor's cause of death was different, with 82% of donor !60 years old succumbing to a cerebrovascular accident (CVA), compared with 41% of younger donor dying from head trauma ( p = 0.005). No considerable differences were noted between the two groups with regard to inotrope dependence, ischemic time, donor/ recipient weight ratio, and matching a male recipient with female donor heart (Table 3) .
Short-term results: In our experience, patients transplanted with donor !60 years experienced, during the postoperative phase, a higher incidence of severe right
Use of donor hearts at least of 60 years of age at our center, comparison to total number of heart transplantation and donor mean age. HTx: heart transplant. Long-term results: The incidence of major post-transplant complications, such as acute rejections, infections, CAV, and renal failure, were comparable in the two groups (Table 5) . Freedom from acute rejection treated was 39.8% and 39.1% at 1 and 3 years in patients transplanted with younger donors, which was comparable to that of patients of group O, being, respectively, 43.2% and 43.0%. Freedom from CAV was similar between the two groups and was 96.0%, 87.1%, and 67.4% in group Y at 1, 3, and 9 years versus 89.3%, 78.1%, and 69.2% in group O patients. Hemodynamic data and left ventricle echocardiographic ejection fraction were similar during the follow-up between the two groups.
Overall actuarial survival of patients receiving donor hearts at least 60 years of age was significantly reduced (logrank test, p < 0.0001) compared with recipients of donor (Fig. 2) . However, if patients who did not survive the first 30 days were excluded from the analysis, the long-term survival was no longer influenced by donor age, and was comparable between the two groups and was, respectively, 97.3% and 87.7% at 1 and 5 years in group Y versus 90.6% and 79.4% in group O. Among recipients of donor hearts at least 60 years of age, 10 late deaths (29%) occurred during a mean follow-up period of 6.8 AE 5 years (range 0.1-17.7 years). The principal causes of death were neoplasm in four patients and cardiac cause in three patients. Among group Y patients, 227 late deaths occurred (35%) during a mean follow-up period of 7.9 AE 6 years (range 0.1-20 years). The principal causes were neoplasm in 73 patients and CAV in 54 patients.
Discussion
HTx remains the gold standard in the treatment of endstage HF in appropriate candidates, with a median posttransplant survival of 10 years [3] . However, despite its favorable outcomes, the overall heart transplant impact is limited due to the critical scarcity of donor organs. Therefore, the disparity between the supply and demand for HTx continuously increased, stimulating intense efforts to expand the donor pool. To meet the increasing demand for organs, the original stringent criteria for donor eligibility have been extended. To expand the donor pool, many centers have begun to accept marginal donor hearts that otherwise would go unused. Expanded donor criteria include the use of donors substantially smaller than the recipients, donors with coronary artery disease that may require coronary artery bypass grafting (CABG), donors with left ventricular dysfunction, or donors from older age groups [1] . Even if early in the experience of HTx the upper limit of donor age was 35 years [10] and major concerns were present about older donors' use, particularly related to a greater susceptibility of early irreversible graft failure [11] , the transmission of coronary artery disease (CAD), or valvular degeneration from the donor heart [12] , nowadays, older donor hearts have been used with increasing frequency. As a matter of fact, mean donor age for HTx increased from a low of 23 years in 1983 to 31 years by 1999, and has reached 33.6 years in the most recent cohort [3] . Further, at our center, mean donor age increased constantly over the years, from a low of 25 years at the beginning of our experience to 37 years by the 1990s, and reached 44.8 years in the most recent cohort.
Several small, single-center studies have shown that the use of older donor hearts does not impart diminished survival to the recipients [4, 5, 13, 14] . By contrast, large multiinstitutional studies from the Cardiac Transplant Research Database and the International Heart and Lung Transplantation Society (IHLTS) reported increased mortality in heart transplant recipients receiving older donor hearts [3, 15, 16] . Our experience is consistent with these multi-institutional findings and supports previous single-center studies of poorer survival in recipients of older donor hearts [17, 18] . The 711 patients, who received a heart from donors <60 years, had a 1-month mortality of 10%, while the 50 patients, who underwent HTx with an allograft of a donor !60 years, had 32% early postoperative mortality. Our data supported the findings of Lietz and colleagues [18] showing that the correlation between older donor age and poor survival was confined to the very early perioperative period, and no further association between older donor age and survival was found beyond the first post-transplant month. Patients' hearts transplanted with donors !60 years of age were also more likely to die of early graft failure, unresponsive to any pharmacologic and mechanical support, than recipients of donors <60 years of age, at 62% versus 47%, respectively. Although such a pattern of early post-transplant death often suggests a recipient-related effect, as Gupta and colleagues [19] observed, we did not find a difference in 'severity' of HF (as estimated by list status, cardiac output, inotrope support, VAD requirement, pulmonary artery pressure, and renal disease) to explain this finding. However, if we analyze the characteristics of the 16 HTx patients of group O who died, they were older, received an older donor heart, died of CVA, and had a longer ischemic time in comparison to the 36 surviving HTx patients. All these elements are consistent with the ISHLT data and other authors' experiences that have shown that long ischemic time increases the risk for death in recipients, who received heart from donors older than 50 years [3, 15, 17] . Even if, at the present time, there is lack of knowledge regarding the relationships between the use of heart from older donors to the causes of high postoperative mortality, approaches that optimize survival have to be pursued. These include careful selection of recipients and donors, preferring local donors or those from hospitals relatively close to the recipient site to reduce ischemic time, as well as reduce coincident risks, and choosing recipients with less co-morbidity.
Considering the high risk of postoperative mortality in patients transplanted with older donor hearts, it is important to keep in mind that patients with end-stage HF face a significant risk of death while awaiting HTx. Bennet and colleagues [20] and, more recently, Lietz and colleagues [18] showed that, despite an initial risk resulting from the transplant procedure, there was a clear, long-term survival benefit for Status I recipients, who received older donor hearts. Although recipients of older donor hearts had poorer early survival than did recipients of hearts from younger donors, it was still much more beneficial, in terms of a risk/ benefit ratio, to transplant a patient with an older donor heart than to remain indefinitely on the transplant waiting list. These benefits may be even more evident in unstable United Network for Organ Sharing (UNOS) status I patients who are critically ill and who appear to be deteriorating despite hemodynamic support [18] . From the analysis of ISHLT Registry data [3] , donor age not only strongly predicts short-term mortality but also adversely affects long-term survival. In a study by Loebe and colleagues, the incidence of post-transplant cardiac events was higher when donors older than 50 years of age were used, in terms of increased rate of percutaneous transluminal coronary angioplasty, CABGs, and retransplantation [5] . In our experience, long-term events were similar between the two groups even if the number of patients at risk was different. No differences were noted in terms of incidence of hypertension, diabetes, and severe renal failure. Although single-center experience and a large multi-institutional study from the ISHLT reported that elevated donor age is an independent predictor of CAV development [18, 21, 22] , in our population, freedom from CAV was similar between the two groups. This should be related also with the fact that, in our experience, almost all older donors (48/50) underwent angiography with evidence of normal coronary arteries.
Considering our results, we believe that it should be possible to increase the cardiac donor pool by accepting allografts from donors !60 years of age only in selected 'ideal' cases. We believe that a meticulous donor evaluation is needed, and only older donor hearts with negative cardiac history, normal electrocardiogram and echocardiogram, low inotropic support, normal coronary angiogram, and an expected short ischemic time may fill this void. At the same time, a careful recipient risk assessment has to be made, and the use of these hearts should be reserved for a selected population, such as the status 1 patients, who are at higher risk of mortality on the waiting list.
Study limitation
This study has the limitations associated with a retrospectively performed analysis.
Because the first transplantation with a donor older than 60 years was performed in 1990, we carried out our analysis excluding heart transplants performed before 1990.
Although the follow-ups of the two recipient groups were similar, the percentage of survivors receiving older donor hearts was considerably less than those receiving younger hearts.
Regarding CAV, our study has the limitation that diagnosis was made by angiography that was the cornerstone of the diagnosis of CAV before the advent of intravascular ultrasound (IVUS), a more sensitive method to detect the early stages of CAV.
As a confounding bias, it is possible that donors !60 years were allocated to sicker recipients, who had a higher probability of death if they remained on the waiting list.
